U.S. markets open in 8 hours 57 minutes
  • S&P Futures

    4,386.50
    +6.75 (+0.15%)
     
  • Dow Futures

    34,792.00
    +71.00 (+0.20%)
     
  • Nasdaq Futures

    14,968.50
    +15.75 (+0.11%)
     
  • Russell 2000 Futures

    2,213.90
    +3.00 (+0.14%)
     
  • Crude Oil

    71.19
    -0.07 (-0.10%)
     
  • Gold

    1,814.90
    -7.30 (-0.40%)
     
  • Silver

    25.39
    -0.19 (-0.74%)
     
  • EUR/USD

    1.1884
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.1740
    -1.2390 (-100.00%)
     
  • Vix

    19.46
    -18.24 (-100.00%)
     
  • GBP/USD

    1.3904
    +0.0021 (+0.15%)
     
  • USD/JPY

    109.1470
    -0.1620 (-0.15%)
     
  • BTC-USD

    38,755.68
    -1,112.11 (-2.79%)
     
  • CMC Crypto 200

    945.13
    -15.76 (-1.64%)
     
  • FTSE 100

    7,081.72
    +49.42 (+0.70%)
     
  • Nikkei 225

    27,544.78
    -236.24 (-0.85%)
     

Seres shares fall 55% after the company says its colitis drug failed in mid-stage clinical trial

Seres shares fall 55% after the company says its colitis drug failed in mid-stage clinical trial

Shares of Seres Therapeutics Inc. tumbled 55.4% in premarket trading on Thursday after the company said a mid-stage study testing its experimental ulcerative colitis drug failed. As a result, Seres closed the open-label and maintenance part of the trial. Seres' stock is down 15.0% so far this year, while the S&P 500 has gained 15.1%.